2 days ago · BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India: February 24, 2025 — Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now available to patients in the United States, and is one …

Dec 1, 2024 · YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

2 days ago · Biocon Biologics has officially launched its biosimilar ustekinumab-kfce (Yesintek) in the United States. 1. This sixth biosimilar to ustekinumab (Stelara; Janssen Biotech) is indicated for use in various conditions, including moderate to severe psoriasis, psoriatic arthritis, ulcertivecolitis, and Crohn disease.

Dec 2, 2024 · YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

Dec 15, 2024 · Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESINTEK®, an Ustekinumab biosimilar …

Dec 2, 2024 · The FDA has approved Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara (ustekinumab) for the treatment of inflammatory bowel disease, plaque psoriasis, and psoriatic arthritis.1 Ustekinumab is a humanized immunoglobulin G1k (IgG1k) monoclonal antibody used to treat psoriatic arthritis, plaque psoriasis, and inflammatory ...

1 day ago · Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United States. The product is one of the first Stelara (ustekinumab) biosimilar market entrants in the country, claimed company.. YESINTEK is approved for the treatment of …

Source: Biocon Biologics Ltd. Yesintek Indications and Important Safety Information. INDICATIONS. Yesintek is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA).

1 day ago · BRIDGEWATER, N.J. and BENGALURU, India, Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now available to patients in the United States, and is one of the first …

1 day ago · Also Read: Biocon Biologics CEO expects core margin improvement, outlines upcoming launches YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling-associated immune-mediated diseases. Clinical studies showed that YESINTEK is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and immunogenicity ...